TRANSFORMATIVE CANCER THERAPIES. TARGETED IMPACT.
Immunotherapy represents one of the greatest advances for people living with cancer, but off-target effects remain a challenge in the clinical setting.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
Our technology is designed to unleash validated and proven proinflammatory mechanisms on tumors while preventing unwanted side effects on non-target tissue. We create systemically delivered targeted therapies that address the limitations of immuno-oncology.
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies.
OUR GOAL IS TO TRANSFORM THE LIVES OF CANCER PATIENTS
INNOVATIVE CANCER THERAPIES DIFFERENTIATED BY DESIGN
We are advancing a novel class of cancer biotherapeutics designed to enhance the body’s immune response to cancer.
These conditionally activated proinflammatory immune modulators, called INDUKINE™ molecules, are systemically administered in an inactive form and are selectively activated to deliver full biological potency of cytokines upon entering the tumor microenvironment.
Our team of experienced scientists invented our proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.


What’s in a name?
The company name is a powerful analogy to our scientific approach. A werewolf is a creature that goes unnoticed in day-to-day life but transforms into a dangerous predator under specific conditions. That is exactly what the medicines that we are developing do.
Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.
Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.
Werewolf in the news
Explore the articles, events, and news coverage we’ve received.
February 8, 2021
Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer
Veteran life sciences financial executive brings over 25 years finance and capital markets expertise Cambridge,
Read More
January 7, 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Financing accelerates Werewolf’s pipeline of systemically delivered, conditionally activated INDUKINE™ molecules into clinical stage development
Read More
November 9, 2020
Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer
Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for
Read More
Join Our Team
Are you someone who makes things happen? Do you want to work at a company that embraces the same ideals? We’re looking for vibrant, creative, forward-thinking people to join our team. Click the link below and let us know that you’re interested. We’d love to talk to you.
Research Associate/Associate Scientist
The successful candidate will be a creative scientist, with strong problem-solving skills and demonstrated experience in protein biochemistry and antibody/therapeutic
Full Job Description
Research Associate/Sr. Research Associate, Immunology
The successful candidate will be an experienced research associate who will contribute to the design and execution of our experimental
Full Job Description